hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 weeks in a Phase 1b/2a trial.
Citing